ADC Therapeutics Secures $60 Million to Advance ZYNLONTA Commercialization and Prepare for 2027 Relaunch
核心洞察
ADC Therapeutics raised $60 million through a private placement led by TCGX (搜索) with participation from Redmile Group (搜索) and existing investors to support commercial expansion of ZYNLONTA.
The funds will strengthen the company's financial position ahead of a potential ZYNLONTA relaunch in 2027, with the transaction expected to close on October 27, 2025.
ZYNLONTA is the first and only CD19 (搜索)-directed antibody drug conjugate approved by FDA and EMA for treating relapsed or refractory large B-cell lymphoma (搜索) after two or more lines of therapy.
ADC Therapeutics has announced a $60 million private investment in public equity (PIPE) financing to support the next phase of growth for its oncology portfolio, with particular focus on expanding commercialization of ZYNLONTA, its FDA- and EMA-approved cancer treatment.
The Lausanne-based biotech company, a global pioneer in antibody-drug conjugates (ADCs), secured the financing through a round led by TCGX (搜索), with participation from Redmile Group (搜索) and other existing investors. The company will issue 11.3 million common shares at $4.00 per share and 3.8 million pre-funded warrants at $3.90 each, with the transaction expected to close on October 27, 2025.
Strategic Focus on ZYNLONTA Expansion
The financing will provide approximately $57.6 million in net proceeds after expenses, which ADC Therapeutics plans to use primarily for commercial expansion of ZYNLONTA and to strengthen its financial position ahead of a potential relaunch in 2027. "This financing enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA and further strengthens our balance sheet," said Ameet Mallik, CEO of ADC Therapeutics. "We believe we are well-positioned to accelerate our trajectory towards long-term sustainable growth."
The funding is expected to extend the company's cash runway into 2028, providing financial stability for its ongoing operations and development programs.
ZYNLONTA's Clinical Profile and Market Position
ZYNLONTA (loncastuximab tesirine-lpyl) represents a significant advancement in targeted cancer therapy as the first and only CD19 (搜索)-directed ADC approved for adult patients with relapsed or refractory large B-cell lymphoma (搜索) after two or more lines of systemic therapy. The treatment has received approval from both the U.S. Food and Drug Administration under accelerated approval and the European Medicines Agency under conditional approval.
The drug targets a broad spectrum of B-cell malignancies (搜索), including diffuse large B-cell lymphoma (搜索) (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma (搜索). Clinical trials included heavily pre-treated patients with a median of three prior lines of therapy, encompassing difficult-to-treat populations including patients who did not respond to first-line therapy, those refractory to all prior lines of therapy, patients with double/triple hit genetics, and those who had undergone stem cell transplant and CAR-T therapy.
Mechanism of Action and Development Pipeline
ZYNLONTA operates through a sophisticated mechanism that combines targeted delivery with potent cytotoxic effects. Once bound to a CD19 (搜索)-expressing cell, the ADC is internalized, where enzymes release a pyrrolobenzodiazepine (PBD) payload. This potent payload binds to the DNA minor groove with minimal distortion, remaining less visible to DNA repair mechanisms, ultimately resulting in cell cycle arrest and tumor cell death.
Beyond its current approved indication, ZYNLONTA is being evaluated in combination studies for other B-cell malignancies (搜索) and in earlier lines of therapy, potentially expanding its therapeutic applications.
Company Background and Market Position
Founded in 2011 and headquartered at the Biopôle life sciences campus in Lausanne, Switzerland, ADC Therapeutics has established itself as a commercial-stage global leader in the ADC field. The company maintains operations in London and New Jersey, positioning it strategically across key pharmaceutical markets.
The company's presence within the Biopôle ecosystem reinforces Western Switzerland's reputation as a European hub for advanced cancer research and precision medicine. ADC Therapeutics continues to advance its proprietary ADC technology platform, with multiple ADCs in ongoing clinical and preclinical development beyond ZYNLONTA.
Jefferies (搜索) is acting as placement agent for the PIPE transaction, with Davis Polk & Wardwell LLP and Homburger AG serving as legal advisors to ADC Therapeutics.